Medicare will increase payment for certain "high-throughput" COVID-19 diagnostic tests to $100 to expand testing capacity and speed results during the public health emergency, the Centers for Medicare & Medicaid Services announced yesterday. The tests can process more than 200 specimens a day but require specially trained technicians and more time-intensive processes to assure quality. CMS expects the payment increase to allow laboratories to expand testing, particularly to vulnerable nursing home patients. Medicare administrative contractors previously paid about $51 for these clinical laboratory diagnostic tests under Medicare Part B.

Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Centers for Medicare & Medicaid Services released a proposed rule Oct. 16 seeking to codify regulations that will improve the accuracy of Medicare…
Headline
The Centers for Medicare & Medicaid Services announced that it will exercise enforcement discretion for inpatient rehabilitation facility admissions from…
Headline
The Centers for Disease Control and Prevention issued a reminder Oct. 14 that the declaration supporting the emergency use of COVID-19 in vitro diagnostics…
Headline
The Centers for Medicare & Medicaid Services has released 2027 Medicare Advantage plan information, including star ratings, through the Medicare Plan…